Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00341198
Other study ID # 999902166
Secondary ID 02-E-N166
Status Completed
Phase N/A
First received June 19, 2006
Last updated June 30, 2017
Start date April 2, 2002
Est. completion date December 12, 2006

Study information

Verified date December 12, 2006
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Autoimmune diseases may involve nearly any organ and are characterized by abnormal activation or response of certain cells. Evidence suggests that farm work, exposure to silica from farming activities and exposure to pesticides may contribute to the development of autoimmune disease. Associations between autoimmune diseases and farming, however, have not been extensively investigated, and exposure data in the currently available studies are extremely limited.

One of the major challenges in conducting population-based research on autoimmune diseases is case ascertainment. Self-report of previous diagnosis has proven to be unreliable. This protocol outlines a strategy to confirm self-reported diagnoses of systemic autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and Sjogren syndrome) within the Agricultural Health Study group (AHS; a group of licensed pesticide applicators and spouses who completed a questionnaire). The confirmed cases will constitute a refined case group to allow analyses of pesticides and other farming-related exposures as possible risk factors for these diseases using data that have already been collected.

Subjects will be selected from participants in the AHS who reported one of the diseases being studied. A short telephone interview will be conducted with participants, who will be requested to provide written consent for review of information from medical records. To confirm the self-diagnosis, participants' physicians will be contacted. Specific information will be requested in the form of a checklist. Responses will be reviewed for evidence of diagnosis and classified as confirmed, probable, physician-diagnosed, or unconfirmed.

Secondary objectives of this study are to:

- assess the correct interpretation of conflicting self-reports that are provided at two different times.

- evaluate the usefulness of specific questions that could potentially be used in future studies to validate self-reported cases of rheumatoid arthritis in men.


Description:

Farming-related exposures (including pesticides and silica) may contribute to the etiology of autoimmune diseases. However, associations between autoimmune diseases and farming have not been extensively investigated, and exposure data in the currently available studies is extremely limited. One of the major challenges in conducting population-based research on autoimmune diseases is case ascertainment. Self-report of previous diagnosis has been shown to be very unreliable. This protocol outlines a strategy to confirm self-reported diagnoses of systemic autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and Sjogren syndrome) within the Agricultural Health Study (AHS) cohort. The confirmed cases will constitute a refined case group to allow etiologic analyses of pesticides and other farming-related exposures as possible risk factors for these diseases using data that have already been collected. The codes can also be used in a nested case-control study that could be designed to collect additional exposure data (for example, on silica-related exposures).


Recruitment information / eligibility

Status Completed
Enrollment 700
Est. completion date December 12, 2006
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility - INCLUSION CRITERIA:

Agricultural workers and their spouses.

EXCLUSION CRITERIA:

Children will not be included.

There are no exclusions based on ethnicity or race.

Participants who are unable to complete a telephone interview because of chronic illness (including cognitive impairment) or language or hearing difficulties will not be eligible.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Battelle Centers for Public Health Research and Evaluation Durham North Carolina
United States University of Iowa Iowa City Iowa
United States NIEHS, Research Triangle Park Research Triangle Park North Carolina

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Environmental Health Sciences (NIEHS)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, Kazatchkine MD, Gilquin J, Viard JP. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000 Nov;85(11):4254-7. — View Citation

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01934764 - Identification of Correlations Between Reaction to Biotine and Autoimmune Diseases N/A
Recruiting NCT01665196 - 18F-FDG PET/CT for IgG4-Related Disease Early Phase 1
Withdrawn NCT02948855 - Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
Completed NCT01815996 - Identify Clinical Conditions That Increase Circulating DNA Levels
Completed NCT02434458 - Sudoscan in Patients With Autoimmune Disorders N/A
Completed NCT02263703 - Immunogenicity of HPV Vaccine in Immunosuppressed Children Phase 3
Completed NCT00013689 - Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome Phase 1
Completed NCT00340600 - Continuation of Follow-up of DES-Exposed Cohorts
Not yet recruiting NCT05894707 - Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers Phase 1
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Active, not recruiting NCT00716066 - Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Phase 2
Completed NCT00351377 - Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate Phase 3
Completed NCT00114530 - Scleroderma: Cyclophosphamide or Transplantation Phase 2/Phase 3
Completed NCT00001630 - Treatment of Autoimmune Thrombocytopenia (AITP) Phase 1
Completed NCT00372177 - The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis Phase 1/Phase 2
Completed NCT00065390 - Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome Phase 1
Completed NCT00001658 - Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Phase 4
Recruiting NCT03816345 - Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Phase 1
Completed NCT00001306 - Steroid Therapy in Autoimmune Premature Ovarian Failure N/A
Recruiting NCT03715699 - Leflunomide Treatment for IgG4-RD N/A